重度放射性淋巴细胞减少对实体瘤总生存的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入20项研究共21个队列,评估放射性淋巴细胞减少(RIL)与实体瘤患者总生存(OS)的预后关系。结果显示,≥3级RIL相比0-2级RIL的合并校正风险比(aHR)为1.65(95%CI 1.43-1.90),4级RIL相比0-3级RIL的aHR为1.53(95%CI 1.24-1.90)。亚组分析中,≥3级RIL在脑肿瘤、肺癌和胰腺癌队列中均显示显著不良预后影响。
要点
- ≥3级RIL与实体瘤放疗患者OS显著不良相关(合并aHR 1.65,95%CI 1.43-1.90)。
- 4级RIL相比0-3级RIL亦显示显著不良预后(aHR 1.53,95%CI 1.24-1.90)。
- ≥3级RIL的不良影响在脑肿瘤、肺癌和胰腺癌队列中一致。
核心结论
- ≥3级淋巴细胞减少与接受放疗的实体瘤患者总生存显著不良相关。
- 该不良预后关联在脑、胸部及上腹部肿瘤中表现一致。
研究设计与样本
- 系统检索PubMed/MEDLINE和Embase,纳入报告RIL与实体瘤生存预后关系的干预性和预后性研究。
- 共纳入20项合格研究中的21个队列,使用随机效应模型计算合并校正风险比(aHR)。
- 采用荟萃回归对不同患者、肿瘤、治疗和研究相关特征进行亚组分析。
主要发现
- ≥3级RIL对比0-2级RIL与OS显著相关(n=16;合并aHR 1.65;95%CI 1.43-1.90)。
- 4级RIL对比0-3级RIL与OS显著相关(n=5;aHR 1.53;95%CI 1.24-1.90)。
- aHR间存在中度异质性,主要归因于7项可能因模型过拟合而高估aHR的研究。
- 亚组分析显示≥3级RIL在4个脑肿瘤队列(aHR 1.63;95%CI 1.06-2.51)、4个肺癌队列(aHR 1.52;95%CI 1.01-2.29)和3个胰腺癌队列(aHR 1.92;95%CI 1.10-3.36)中均有显著预后影响。
临床怎么用
- 放疗临床中应将≥3级淋巴细胞减少视为不良预后标志,关注脑、胸部及上腹部肿瘤患者。
- 该结果为探索减轻淋巴细胞减少策略以改善生存提供了依据。
局限性
- 合并aHR间存在中度异质性,部分源于7项可能模型过拟合的研究高估aHR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Emerging evidence suggests a detrimental prognostic association between radiation-induced lymphopenia (RIL) and pathologic response, progression-free survival, and overall survival (OS) in patients who undergo radiation therapy for cancer. The aim of this study was to systematically review and meta-analyze the prognostic impact of RIL on OS in patients with solid tumors. METHODS AND MATERIALS: PubMed/MEDLINE and Embase were systematically searched. The analysis included intervention and prognostic studies that reported on the prognostic relationship between RIL and survival in patients with solid tumors. An overall pooled adjusted hazard ratio (aHR) was calculated using a random-effects model. Subgroup analyses for different patient-, tumor-, treatment-, and study-related characteristics were performed using meta-regression. RESULTS: Pooling of 21 cohorts within 20 eligible studies demonstrated a statistically significant association between OS and grade ≥3 versus grade 0-2 RIL (n = 16; pooled aHR, 1.65; 95% confidence interval [CI], 1.43-1.90) and grade 4 RIL versus grade 0-3 (n = 5; aHR, 1.53; 95% CI, 1.24-1.90). Moderate heterogeneity among aHRs was observed, mostly attributable to overestimated aHRs in 7 studies likely subject to model-overfitting. Subgroup analysis showed significant prognostic impact of grade ≥3 RIL in 4 brain tumor (aHR, 1.63; 95% CI, 1.06-2.51), 4 lung cancer (aHR, 1.52; 95% CI, 1.01-2.29), and 3 pancreatic cancer (aHR, 1.92; 95% CI, 1.10-3.36) cohorts. CONCLUSIONS: This meta-analysis demonstrates a significant detrimental prognostic association between grade ≥3 lymphopenia and OS in patients receiving radiation therapy for solid tumors. This finding appears consistent for tumors of the brain, thorax, and upper abdomen and provides an imperative to further elucidate the potential survival benefit of lymphopenia-mitigating strategies.
引用
- Damen PJJ, Kroese TE, van Hillegersberg R, et al. The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2021. PMID: 34329738. doi:10.1016/j.ijrobp.2021.07.1695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。